landiolol

Contraindicated in:

Hypersensitivity;
Severe sinus bradycardia, sick sinus syndrome, or >1st-degree heart block;
Decompensated HF;
Cardiogenic shock;
Pulmonary hypertension;
Moderate or severe hepatic impairment.

Use Cautiously in:

Hypovolemia (↑ risk of hypotension);
1st-degree heart block, sinus node dysfunction, or conduction disorders (↑ risk of bradycardia and heart block);
Reactive airway disease;
Diabetes mellitus (may ↑ risk mask signs of hypoglycemia);
Prinzmetal angina (↑ risk of angina);
Untreated pheochromocytoma (initiate only after alpha blocker therapy started);
Raynaud disease or peripheral vascular disease;
Renal impairment (↑ risk of hyperkalemia);
Mild hepatic impairment;
Metabolic acidosis (↑ risk of hyperkalemia renal tubular acidosis);
Hyperthyroidism (may mask symptoms);
History of severe allergic reactions (intensity of reactions may be ↑);
OB: Safety not established in pregnancy;
Lactation: Safety not established in breastfeeding;
Pedi: Safety and effectiveness not established in children;
Geri: Older adults may have ↑ sensitivity to beta blockers; initial dose ↓ recommended.

Adv. Reactions/Side Effects ⬆ ⬇

CV: bradycardia, HF, hypotension

Endo: hypoglycemia

F and E: hyperkalemia

Local: infusion site reactions

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)

Interactions ⬆ ⬇

Drug-drug:

↑risk of bradycardia when used with digoxin, verapamil, diltiazem, clonidine, or ivabradine.
↑risk of depressed myocardial contractility when used with negative inotropes, including verapamil or diltiazem.
Concurrent use with amphetamines, cocaine, ephedrine, epinephrine, norepinephrine, phenylephrine, or pseudoephedrine may result in unopposed alpha-adrenergic stimulation (excessive hypertension, bradycardia).
May ↓ the beneficial beta₁-cardiovascular effects of dopamine or dobutamine.
Use cautiously within 14 days of MAO inhibitor therapy (may result in hypertension).

Availability ⬆ ⬇

Lyophilized powder for injection: 280 mg/vial

Route/Dosage ⬆ ⬇

IV (Adults ): Normal cardiac function: 9 mcg/kg/min infusion initially; then ↑ by 9 mcg/kg/min every 10 min to achieve adequate ventricular rate control (max dose = 36 mcg/kg/min). Impaired cardiac function: 1 mcg/kg/min infusion initially; then ↑ by 1 mcg/kg/min every 15 min to achieve adequate ventricular rate control (max dose = 36 mcg/kg/min).

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Blocks stimulation of beta₁(myocardial)-adrenergic receptors. Does not usually affect beta₂(pulmonary, vascular, uterine)-adrenergic receptor sites.

Therapeutic effects:

Decreased ventricular rate (HR) in atrial fibrillation or atrial flutter.

Classifications ⬆ ⬇

Therapeutic Classification: antiarrhythmics

Pharmacologic Classification: beta blockers

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Well distributed to tissues.

Metabolism/Excretion: Primarily metabolized by pseudocholinesterases and carboxylesterases in the plasma to an active metabolite.

Half-Life: Primarily excreted in urine as metabolites (8% as unchanged drug).

Time/Action Profile ⬆ ⬇

(↓ HR)

ROUTE	ONSET	PEAK	DURATION
IV	rapid	10 min	minutes

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of landiolol. Advise patient to read Patient Information before starting therapy.
Advise patients to change positions slowly to minimize orthostatic hypotension.
Advise patient to call right away for chest pain, trouble breathing, nausea, unusual sweating, light-headedness, feeling faint, itchiness, numbness in hands or feet, or warmth/redness in upper body (face, neck, arms, chest).
Rep: Advise women of reproductive potential to notify health care professional if pregnant or breastfeeding. May cause fetal bradycardia. Monitor neonates exposed to landiolol during pregnancy and labor for hypotension, hypoglycemia, bradycardia, and respiratory depression, and manage accordingly. Monitor breastfed infants for bradycardia and symptoms of beta blockade, such as lethargy (hypoglycemia).

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

71956- LYOCONTRACT GmbH
- 71956-110-
  - 71956-110-01- 4 BOX in 1 CARTON (71956-110-01) / 25 VIAL, GLASS in 1 BOX / 1 POWDER, FOR SOLUTION in 1 VIAL, GLASS

84381- AOP Orphan Pharmaceuticals GmbH
- 84381-110- RAPIBLYK
  - 84381-110-01- 1 VIAL, SINGLE-DOSE in 1 CARTON (84381-110-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇